First-Line Doublet Chemotherapy for Metastatic Triple-Negative Breast Cancer: Circulating Tumor Cell Analysis of the tnAcity Trial

PURPOSE: Circulating tumor cells (CTCs) are prognostic biomarkers in metastatic breast cancer, but their role in predicting treatment outcomes in metastatic triple-negative breast cancer (mTNBC) is less clear. The tnAcity trial demonstrated a significant progression-free survival (PFS) benefit with...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Minetta C, Janni, Wolfgang, Georgoulias, Vassilis, Yardley, Denise A, Harbeck, Nadia, Wei, Xin, McGovern, Desmond, Beck, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6913260/
https://www.ncbi.nlm.nih.gov/pubmed/31849532
http://dx.doi.org/10.2147/CMAR.S208712

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6913260/
https://www.ncbi.nlm.nih.gov/pubmed/31849532
http://dx.doi.org/10.2147/CMAR.S208712

Ejemplares similares